Floatz logo

Therapeutic Asset Ratings

5,099 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Cytarabine
Testicular Leukemia
Children's Oncology GroupP3B (60)
Darolutamide
Prostate Neoplasm
BayerP3B (60)
Daunomycin
Central Nervous System Leukemia
Children's Oncology GroupP3B (60)
Daunomycin
Testicular Leukemia
Children's Oncology GroupP3B (60)
Decitabine
T Lymphoblastic Leukemia/Lymphoma
M.D. Anderson Cancer CenterP3B (60)
Decitabine
T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer CenterP3B (60)
Dexasone
Central Nervous System Leukemia
Children's Oncology GroupP3B (60)
Dexasone
T Lymphoblastic Leukemia/Lymphoma
Children's Oncology GroupP3B (60)
Dexasone
Ovarian Neoplasm
Zhejiang UniversityP3B (60)
Dexasone
Prostate Neoplasm
Merck Sharp & Dohme LLCP3B (60)
Dexasone
Testicular Leukemia
Children's Oncology GroupP3B (60)
Diclofenac
Sciatica
Pakistan Institute of Medical SciencesP3B (60)
Disitamab Vedotin
Cancer
LaNova Medicines LimitedP3B (60)
Docetaxel
Endometrial Carcinoma
Merck Sharp & Dohme LLCP3B (60)
Docetaxel
Lung Neoplasm
Merck Sharp & Dohme LLCP3B (60)
Docetaxel
Small Cell Lung Carcinoma
Shanghai JMT-Bio Inc.P3B (60)
Durvalumab
Hepatocellular Carcinoma
Amit MahipalP3B (60)
Durvalumab
Hormone Receptor-Positive Breast Cancer
National Cancer Institute (NCI)P3B (60)
Durvalumab
Bladder Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3B (60)
Durvalumab
Lung Cancer
University of ChicagoP3B (60)
Durvalumab
Papillary Renal Cell Carcinoma
AstraZenecaP3B (60)
Durvalumab
Renal Cell Carcinoma
M.D. Anderson Cancer CenterP3B (60)
Edotreotide
Digestive System Neuroendocrine Neoplasm
Jiangsu HengRui Medicine Co., Ltd.P3B (60)
Efanesoctocog Alfa
Severe Hemophilia A
Swedish Orphan BiovitrumP3B (60)
Eliglustat
Gaucher Disease Type III
SanofiP3B (60)
Showing 2351 to 2375 of 5,099 assets
PreviousPage 95 of 204Next